Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL
Patients with heavily pretreated, relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with epcoritamab, a bispecific antibody, had a high overall response rate ...
MRD-Guided Therapy Improves Quality of Life for Patients With CLL
Time-limited treatment with ibrutinib plus venetoclax in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) guided by measurable residual disease ...
CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds
Patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy who achieved a complete response ...
Long-Lasting, Deep Remissions Seen in R/R CLL with Triple Combination Therapy
Using a time-limited triplet combination of acalabrutinib, venetoclax, and obinutuzumab, 93.3% of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) achieved undetectable ...
MRD Helpful in Predicting Progression-Free Survival in CLL
Measurable residual disease (MRD) status shows value in predicting progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) in the era of targeted therapies ...
Venetoclax Plus Obinutuzumab a Viable Option for Newly Diagnosed CLL
Fit patients newly diagnosed with chronic lymphocytic leukemia (CLL) had improved progression-free survival (PFS) when treated with venetoclax plus obinutuzumab compared to ...
CAR-T Therapy Effective for Richter Transformation
Research by Adam S. Kittai, MD, at the Icahn School of Medicine at Mount Sinai in New York, and colleagues has documented commercial anti-CD19 chimeric antigen receptor T-cell ...
Analysis Finds CLL-IPI Performs Poorly When Predicting Survival for Patients Treated With Targeted Therapies
In 2014, the U.S. Food and Drug Administration approved the targeted therapy ibrutinib as a first-line treatment for patients with chronic lymphocytic leukemia (CLL) with TP53 aberration ...
Pirtobrutinib Combinations Effective in Small Study
A study published in Blood suggests that combining the noncovalent BTK inhibitor (BTKi) pirtobrutinib in a time-limited fashion with venetoclax, or with both venetoclax and rituximab ...
Pirtobrutinib Shows Efficacy in Previously Treated Richter Transformation
In patients with Richter transformation (RT), pirtobrutinib — a first-in-class, noncovalent reversible BTK inhibitor (BTKi) — showed promising activity and acceptable safety in a phase I/II trial ...
